NHS and patients’ access to innovative

medicines of top priority

KyΚυριάκος Μικέλληςriakos Mikellis, Cyprus Business Manger at Pfizer, has been elected as the new President of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) for the next two years.

Assuming the position, Mr Mikellis thanked the incumbent President, Mrs Joanna Kozakou, for her valuable contribution over the past year and stressed that KEFEA’s priority for the immediate future was to ensure implementation of a sustainable and efficient National Health System, which will guarantee access to effective, safe and fairly priced medicines for all Cypriot patients.

“There are great challenges ahead and in close cooperation with the state and authorities, we must ensure that the new system eliminates the inequalities that exist today between the public and private sector. Especially now that the patient is being called upon to contribute financially, it is a basic prerequisite for the NHS to offer upgraded services, qualitative healthcare and access to innovative medicines,” said Mr Mikellis.

The position of KEFEA Vice President was assumed by Mr Elad Maron, General Manager of GlaxoSmithKline in Cyprus.

KEFEA was founded in 2006 and represents the innovative pharmaceutical industry in Cyprus as a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its members are the companies GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, Amgen Hellas and Genesis Pharma.